STVN
What one share of Stevanato Group S.p.A. holds
Surgical and Medical Instruments and Apparatus
We are a leading global provider of drug containment, drug delivery and diagnostic solutions as well as engineering solutions to the pharmaceutical, biotechnology and life sciences industries.
Stevanato Group S.p.A.’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2025-12-31; the balance sheet is as of 2025-12-31.
| Sales | $4.91 |
|---|---|
| Profit | $0.58 |
| Capex (buildings and equipment) | $1.09 |
| Free cash flow | $0.09 |
| Dividends | $0.06 |
| Cash and investments | $0.51 |
| Debt | $1.76 |
| Book value | $5.76 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | $2.50 | $0.18 | $0.32 | −$0.12 | — | $1.24 |
| 2020 | $3.14 | $0.37 | $0.42 | $0.31 | — | $1.58 |
| 2021 | $3.95 | $0.63 | $0.50 | $0.12 | — | $3.23 |
| 2022 | $3.91 | $0.57 | $0.94 | −$0.52 | — | $3.61 |
| 2023 | $4.43 | $0.59 | $1.77 | −$1.34 | — | $4.24 |
| 2024 | $4.41 | $0.47 | $1.21 | −$0.59 | — | $4.80 |
| 2025 | $4.91 | $0.58 | $1.09 | $0.09 | — | $5.76 |